Achieve is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction.
Our focus is to address the global smoking health epidemic through the development and commercialization of cytisinicline. Smoking is currently the leading cause of preventable death and is responsible for nearly six million people losing their lives annually worldwide.
Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe for more than 20 years.
It is estimated that over 20 million people have used cytisinicline to help combat nicotine addiction, including over 2,000 patients in investigator-conducted, Phase 3 clinical trials in Europe and New Zealand. Achieve expects to initiate a Phase 2b Optimization Trial in the second half of 2018.